Physical Activity, Sleep, and Quality of Life in Pulmonary Arterial Hypertension: Novel Insights from Wearable Devices
Authors: Hughes Andrew M. , Lindsey Alisha , Annis Jeffrey , Burke Kelly , Master Hiral , Silverman-Lloyd Luke G. , Garry Jonah D. , Blaha Michael J. , Berman Rosenzweig Erika S. , Frantz Robert P. , Hassoun Paul M. , Horn Evelyn M. , Leopold Jane A. , Rischard Franz P. , Larive Brett , Hill Nicholas S. , Erzurum Serpil C. , Beck Gerald J. , Hemnes Anna R. , Brittain Evan L. 
Published: October 2024

AbstractBackgroundReduced functional capacity and poor sleep quality are common in pulmonary arterial hypertension (PAH). We aimed to determine whether Fitbit-derived activity and sleep trends provide clinically meaningful information in patients with PAH.MethodsOur prospective observational study recruited patients with PAH from across the United States. Participants with PAH wore a Fitbit device for 12-weeks at baseline and a subgroup with one-year follow-up. A matched control cohort was generated from theAll of UsResearch Program and we evaluated changes in patients with PAH compared to matched controls.ResultsAmong 109 patients with baseline monitoring, average daily steps correlated with 6MWD (r=0.66, p < 0.001) and percent rapid eye movement (REM) sleep (r=0.26, p=0.016). In 44 PAH participants who completed baseline and one-year monitoring, there was a group-time interaction for percent light sleep (p=0.024) and percent REM sleep (p=0.034), which demonstrated that sleep quality worsened in patients with PAH over one year compared to matched controls. Average daily steps in patients with PAH decreased from 5200 [IQR 3212 – 7458] at baseline to 4651 [IQR 2912 – 6827] at one year (p=0.008). Compared to matched controls, activity levels were significantly lower in patients with PAH at both time points.ConclusionsOur study demonstrated the potential clinical value of wearable devices by showing that activity and sleep quality are reduced in PAH compared to matched controls and these measures decline over time. Future studies should investigate if monitoring these health behaviors detects early functional decline and whether targeted interventions may improve outcomes.Prior Abstract Publication/PresentationSome of the data presented in this manuscript have been included in the following abstracts:Hughes A, Annis J, Hemnes A, Lindsey A, Burke K, Brittain E, and the PVDOMICS Study Group. Sleep Patterns and Quality of Life in Pulmonary Arterial Hypertension. Presented at the American Heart Association (AHA) Scientific Sessions, November 2023, Philadelphia, PA.Hughes A, Annis J, Hemnes A, Lindsey A, Burke K, Horn EM, Brittain E, and the PVDOMICS Study Group. The Role of Long-Term Daily Activity Monitoring for the Assessment of Functional Capacity in Pulmonary Arterial Hypertension. Presented at the American Thoracic Society International Conference, May 2023, Washington D.C.Hughes A, Annis J, Hemnes A, Lindsey A, Burke K, Horn EM, Brittain E, and the PVDOMICS Study Group. Long-Term Daily Activity is Associated with Exercise Capacity and Quality of Life in Pulmonary Arterial Hypertension. Presented at the American Heart Association (AHA) Scientific Sessions, November 2022, Chicago, IL.